308067-58-5|Human immunoglobulin G|Human immunoglobulin G|-范德生物科技公司

Human immunoglobulin G

NMR下载 COA and HPLC MSDS下载
names：
Human immunoglobulin G
CAS号：
308067-58-5
MDL Number：
MF(分子式)： MW(分子量)：
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
DBK500664-500mg	500mg		¥ 0.00	¥ 0.00		Get quote	- +	¥ 0.00
DBK500664-100mg	100mg		¥ 0.00	¥ 0.00		Get quote	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	人免疫球蛋白G
英文别名	Human immunoglobulin G
CAS号	308067-58-5
SMILES
Inchi
InchiKey
分子式 Formula
分子量 Molecular Weight
闪点 FP	NA
熔点 Melting point	NA
沸点 Boiling point	NA
Polarizability极化度
密度 Density	NA
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Liquid
储藏条件 Storage conditions

Human immunoglobulin G使用注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害。
3.取样品的移液枪头需及时更换，必要时为避免交叉污染尽可能选择滤芯吸头。
4.称量药品时选用称量纸，并无风处取药和称量以免扬撒，试剂的容器使用前务必确保干净，并消毒。
5.取药品时尽量采用多个药勺分别使用，使用后清洗干净。
6.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染。
大规格定制：定制产品请将信息发送至sales@bio-fount.com。
Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

产品说明	Organic Acids
Introduction	Sulfametopyrazine is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors ofp-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.
Application1	IVIg interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also impacts different effector cells of the immune system (B and T lymphocytes, dendritic cells, etc.) and regulates a wide range of genes. Its main mechanism of actions are believed to be Fc-dependent and F(ab')2-dependent. IVIg competitively blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and suppressing platelet depletion. IVIg contains a number of different antobodies, which prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage “tagging” or neutralization (via binding) of pathogen toxins. Intact IVIg and F(ab′)2 fragments of IVIg can also neutralize the activity of various autoantibodies. By triggering the production of interleukin-1 receptor antagonist, IVIg modulates of the production of cytokines and cytokine antagonists. It also prevents the generation of the C5b-9 membrane attack complex and subsequent complement-mediated tissue damage by binding active complement components.TargetActionsOrganismAHigh affinity immunoglobulin gamma Fc receptor IantagonistHumansAHigh affinity immunoglobulin gamma Fc receptor IBantagonistHumansALow affinity immunoglobulin gamma Fc region receptor II-aantagonistHumansALow affinity immunoglobulin gamma Fc region receptor II-bantagonistHumansALow affinity immunoglobulin gamma Fc region receptor II-cantagonistHumansALow affinity immunoglobulin gamma Fc region receptor III-AantagonistHumansALow affinity immunoglobulin gamma Fc region receptor III-BantagonistHumansAComplement C3binderHumansAComplement C4-AbinderHumansAComplement C4-BbinderHumansAComplement C5binderHumans
Application2	Inhibitor
Application3